Staten Biotechnology

Staten is leading the next step in dyslipidemia management. Dyslipidemia is an abnormal amount of lipids or fat in the blood, namely triglycerides, cholesterol, or fat phospholipids. In developed countries most dyslipidemias are hyperlipidemia, i.e. elevation of lipids in the blood, and can be caused by genetic factors, diet, and lifestyle. Reduction of these lipids in the blood is known to have a positive impact in vascular and heart diseases. Staten is developing a human monoclonal antibody with a unique approach towards neutralizing apoC3 – a key molecule in dyslipidemia management – which reduces triglyceride levels and increases removal of atherogenic lipoprotein remnant particles.

Staten Biotechnology

Transistorweg 5J (Building M)

6543 AT Nijmegen

The Netherlands

+31 35 760 65 00


More companies in this area

Alveron Pharma

Alveron Pharma is developing a unique coagulation platform technology with the world’s first cyclodextrin-based anticoagulant reversal drug.


Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial disease.

Gatt Technologies

GATT Technologies is a privately owned, clinical-stage, medical device company.

SPL Medical

SPL Medical is strongly committed to improve MRI imaging to enable a much more precise, effective and patient friendly diagnosis of cancer metastasis.

QM Diagnostics

QM Diagnostics is an internationally operating, independent and innovative diagnostic microbiological laboratory.

We are specialized in health monitoring of small laboratory animals used for biomedical research.


Developing the next generation of percutaneous left ventricular assist devices.

Settle at Novio Tech Campus!

Connect with Novio Tech Campus!